Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down before the market opened on Tuesday. The stock had previously closed at $15.45, but opened at $14.69. Ascentage Pharma Group International shares last traded at $14.6120, with a volume of 3,497 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AAPG. Citigroup assumed coverage on shares of Ascentage Pharma Group International in a report on Wednesday, October 14th. They issued a “buy” rating and a $46.00 target price on the stock. William Blair began coverage on Ascentage Pharma Group International in a report on Friday, October 16th. They set an “outperform” rating for the company. BTIG Research reissued a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Citizens Jmp assumed coverage on Ascentage Pharma Group International in a research note on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price objective on the stock. Finally, JPMorgan Chase & Co. cut their price objective on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a report on Thursday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $43.90.

Ascentage Pharma Group International Stock Up 1.2%

The firm has a fifty day moving average of $15.98 and a two-hundred day moving average of $20.34. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The business had revenue of $22.24 million for the quarter. Sell-side analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.